These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 17317813)

  • 1. New practices in computational modeling.
    Greco WR
    Clin Cancer Res; 2007 Feb; 13(4):1074-5. PubMed ID: 17317813
    [No Abstract]   [Full Text] [Related]  

  • 2. Computational modeling to predict effect of treatment schedule on drug delivery to prostate in humans.
    Hu L; Au JL; Wientjes MG
    Clin Cancer Res; 2007 Feb; 13(4):1278-87. PubMed ID: 17317840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model.
    Gustafson DL; Rastatter JC; Colombo T; Long ME
    J Pharm Sci; 2002 Jun; 91(6):1488-501. PubMed ID: 12115848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrepancies in pharmacokinetic analysis results obtained by using two standard population pharmacokinetics software programs.
    Finkelstein Y; Nava-Ocampo AA; Schechter T; Grant R; St Pierre E; Goldman R; Walker S; Koren G
    Fundam Clin Pharmacol; 2009 Feb; 23(1):53-7. PubMed ID: 19267770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant enhancement of antitumor activity and bioavailability of intracellular pH-sensitive polymeric micelles by folate conjugation.
    Bae Y; Kataoka K
    J Control Release; 2006 Nov; 116(2):e49-50. PubMed ID: 17718965
    [No Abstract]   [Full Text] [Related]  

  • 6. [Preparation of the EPC and HEPC sterically stabilized doxorubicin liposomes and further studies on pharmacokinetics in rats].
    Yu M; Wang Y; Shu G; Zhu Z; Fang S; Wang L
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Jun; 25(3):597-9. PubMed ID: 18693438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
    Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
    J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly (ethylene glycol) prodrug for anthracyclines via N-Mannich base linker: design, synthesis and biological evaluation.
    Zhao YJ; Wei W; Su ZG; Ma GH
    Int J Pharm; 2009 Sep; 379(1):90-9. PubMed ID: 19540322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of the doxorubicin-lactosaminated human albumin conjugate to HCC cells is mediated by the drug moieties.
    Baglioni M; Fiume L; Bolondi L; Farina C; Kratz F; Di Stefano G
    Dig Liver Dis; 2008 Dec; 40(12):963-4. PubMed ID: 18606580
    [No Abstract]   [Full Text] [Related]  

  • 10. [New conjugates of antitumor antibiotic doxorubicin with water-soluble galactomannan: synthesis and biological activity].
    Teviashova AN; Olsuf'eva EN; Preobrazhenskaia MN; Klesov AA; Zomer E; Platt D
    Bioorg Khim; 2007; 33(1):148-55. PubMed ID: 17375669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational drug delivery.
    Haworth IS
    Adv Drug Deliv Rev; 2006 Nov; 58(12-13):1271-3. PubMed ID: 17069930
    [No Abstract]   [Full Text] [Related]  

  • 12. Screening of biochemical modulator by tumor cell permeability of doxorubicin.
    Sadzuka Y; Hatakeyama H; Daimon T; Sonobe T
    Int J Pharm; 2008 Apr; 354(1-2):63-9. PubMed ID: 18054183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro.
    Khdair A; Handa H; Mao G; Panyam J
    Eur J Pharm Biopharm; 2009 Feb; 71(2):214-22. PubMed ID: 18796331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better design of drug-eluting stents using computer modeling.
    Park K
    J Control Release; 2009 Jan; 133(1):1. PubMed ID: 19038297
    [No Abstract]   [Full Text] [Related]  

  • 15. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.
    Bertilaccio MT; Grioni M; Sutherland BW; Degl'Innocenti E; Freschi M; Jachetti E; Greenberg NM; Corti A; Bellone M
    Prostate; 2008 Jul; 68(10):1105-15. PubMed ID: 18437689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological mechanisms of Doxorubicin activity (DOX) - current state of knowledge].
    Łubgan D; Marczak A; Walczak M; Distel L; Jóźwiak Z
    Przegl Lek; 2006; 63(9):782-8. PubMed ID: 17479870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes.
    Han HD; Lee A; Hwang T; Song CK; Seong H; Hyun J; Shin BC
    J Control Release; 2007 Jul; 120(3):161-8. PubMed ID: 17524514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canine anatomic phantom for preclinical dosimetry in internal emitter therapy.
    Padilla L; Lee C; Milner R; Shahlaee A; Bolch WE
    J Nucl Med; 2008 Mar; 49(3):446-52. PubMed ID: 18287264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational models of dementia and neurological problems.
    Duch W
    Methods Mol Biol; 2007; 401():305-36. PubMed ID: 18368373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
    Gabizon A; Isacson R; Rosengarten O; Tzemach D; Shmeeda H; Sapir R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):695-702. PubMed ID: 17549475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.